Skip to main content
Fig. 3 | Journal of Experimental & Clinical Cancer Research

Fig. 3

From: Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma

Fig. 3

The combination of enzastaurin and ibrutinib promoted apoptosis and induced G1 phase arrest. a Combination treatment prompted apoptosis in DLBCL cells. Cells pre-treated with indicated concentrations of ibrutinib in the presence or absence of fixed concentration of enzastaurin for 48 h were stained with annexin V-APC, then apoptosis was assessed using flow cytometry. Apoptosis cells were determined by APC+ cells. b The combination treatment mediated expression of proteins associated with apoptosis in DLBCL cells. After 48 h of exposure to enzastaurin and/or ibrutinib in combination, proteins were extracted from cells of different groups and proteins associated with apoptosis were analyzed by western blot. c Co-treatment with enzastaurin and ibrutinib induced G1 phase arrest in DLBCL cells. Cells were treated with different concentrations of ibrutinib in the presence or absence of fixed concentration of for enzastaurin 48 h, and then stained with propidium iodide (PI). Cell cycle was assessed using flow cytometry. d The combination treatment group mediated alterations in proteins associated with G1/S transition in DLBCL cells. After 48 h of exposure to indicated concentration of enzastaurin and ibrutinib in combination, proteins were extracted from cells of different groups and proteins were analyzed by western blot. Error bars represent the result and SD of three different experiments. * p < 0.05, ** p < 0.01, *** p < 0.001, compared with control group; # p < 0.05, ## p < 0.01 compared with enzastaurin group

Back to article page